MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Revenue of MannKind Corporation (MNKD)
Revenue in 2023 (TTM): $198.96 M
According to MannKind Corporation's latest financial reports the company's current revenue (TTM) is $198.96 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MannKind Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $198.96 M | $136.19 M | $15.13 M | $-10,377,000 | $-11,938,000 |
| 2022 | $99.77 M | $42.27 M | $-56,344,000 | $-87,400,000 | $-112,169,000 |
| 2021 | $75.44 M | $36.59 M | $-61,091,000 | $-80,926,000 | $-91,791,000 |
| 2020 | $65.14 M | $40.5 M | $-45,010,000 | $-57,458,000 | $-57,240,000 |
| 2019 | $63.04 M | $35.06 M | $-38,215,000 | $-51,903,000 | $-59,729,000 |
| 2018 | $27.86 M | $7.38 M | $-75,596,000 | $-86,735,000 | $-86,975,000 |
| 2017 | $11.75 M | $-5,483,000 | $-102,206,000 | $-117,282,000 | $-117,333,000 |
| 2016 | $174.76 M | $124.67 M | $146.54 M | $125.66 M | $125.66 M |
| 2015 | $ | $-140,412,000 | $-344,655,000 | $-368,445,000 | $-368,445,000 |
| 2014 | $ | $ | $-160,181,000 | $-198,382,000 | $-198,382,000 |
| 2013 | $ | $ | $-155,971,000 | $-191,490,000 | $-191,490,000 |
| 2012 | $35 K | $35 K | $-133,742,000 | $-169,774,000 | $-169,366,000 |
| 2011 | $50 K | $50 K | $-123,677,000 | $-160,804,000 | $-160,804,000 |
| 2010 | $93 K | $93 K | $-135,859,000 | $-170,560,000 | $-170,560,000 |
| 2009 | $ | $ | $-190,932,000 | $-220,104,000 | $-220,104,000 |
| 2008 | $20 K | $20 K | $-288,411,000 | $-303,037,000 | $-303,039,000 |
| 2007 | $10 K | $10 K | $-280,806,000 | $-293,187,000 | $-293,190,000 |
| 2006 | $100 K | $100 K | $-225,180,000 | $-230,543,000 | $-230,548,000 |
| 2005 | $ | $ | $-106,946,000 | $-114,337,000 | $-114,338,000 |
| 2004 | $ | $ | $-68,812,000 | $-75,991,000 | $-75,992,000 |
| 2003 | $ | $ | $-58,630,000 | $-65,878,000 | $-65,879,000 |
| 2002 | $ | $ | $-51,354,000 | $-206,263,000 | $-206,265,000 |
| 2001 | $326 K | $326 K | $289 K | $-48,243,000 | $-48,245,000 |
| 2000 | $154 K | $154 K | $-25,446,000 | $-24,659,000 | $-24,661,000 |